Skip to main content
Premium Trial:

Request an Annual Quote

White Papers and Videos

Optimizing Results from Nucleic Acid Isolation

White Paper

This ebook from Cytiva includes articles on optimizing nucleic acid isolation, avoiding bottlenecks in high-throughput NGS sample prep, isolating nucleic acids from clinical samples, moving from column to bead-based DNA isolation, and detecting mutations with liquid biopsies in cancer diagnostics.

Investigating Cell-Free DNA in Liquid Biopsy

White Paper

Liquid biopsy is a revolutionary approach that is opening previously unexpected opportunities in oncology. It empowers the detection and isolation of circulating tumor cells, cell-free DNA, and circulating tumor DNA, drawing on the strength of NGS technologies now available. Many difficulties have been overcome, but there is still no standardized approach for liquid biopsy processing and cell-free DNA analysis. Substantial progress has been made regarding sample preparation and isolation. However, continued progress in reducing genomic DNA contamination and PCR inhibitors is needed to further improve sensitivity.

This white paper from Cytiva discusses the challenges and opportunities in measuring the small amount of cell-free DNA in liquid samples for applications including oncology, organ and transplant medicine, and non-invasive prenatal testing.

Personalized Therapy Selection: Investigation of Multiple Immune-Checkpoints

White Paper

PD1 blockade through monoclonal antibody-based therapy has revolutionized the immunotherapeutic approach against solid tumors. However, only a small number of patients benefit from this treatment due to the lack of accurate methodology such as immunohistochemistry to guide patients that could respond to this immune checkpoint inhibitor therapy. Understanding the tumor microenvironment complexity with a single biomarker is not accurate enough to predict the interaction of the drug in its site of action.

This white paper from Pyxant Labs presents a strategy in which the tumor microenvironment is deeply investigated to guide the patient efficiently toward single immune therapy or combination therapies, highlighting the relevance of simultaneously investigating multiple biomarkers to obtain an accurate picture of the immune contexture.

Proteomics at the Heart of Multiomics Studies

White Paper

Achieving the goal of precision medicine and more targeted therapeutics will require the use of systems biology approaches to understand the molecular mechanisms at work within the human body. This trend is already apparent in scientific research, with more scientists beginning to use multiomics studies to better understand diseases and to help develop the drugs needed to treat them. To this end, the integration of data from high-throughput proteomics technologies is essential, as proteins best represent individual phenotypes and the effects of environmental and lifestyle factors. In other words, proteins best reflect real-time biology, which is key in developing precision medicine.

This e-book from Olink discusses the integration of proteomics data in multiomics, focusing on how combining genetic data with proteomics help researchers identify proteins that cause disease, how proteomics adds value to multiomics studies on complex diseases, and the future of proteomics in multiomics research.

How Digital Pathology Ensures Ongoing Diagnosis in a Time of Crisis

White Paper

This white paper from Tribun Health discusses how digital pathology helped to address challenges within pathology departments precipitated by the COVID-19 pandemic at three hospitals and how they ensured continuity of cancer diagnosis during lockdowns and staff outages.

Four Good Reasons to Switch to Digital Pathology

White Paper

This white paper from Tribun Health discusses the considerations and benefits of transitioning from histopathological diagnosis with a microscope to virtual microscopy using a computer, including meeting the requirements of precision medicine, streamlining workflows, improving flexibility, and enhancing the security and traceability of diagnosis.

Digital Pathology at Paris Saclay Hospital Group: Process, Benefits, and Recommendations

White Paper

This white paper from Tribun Health discusses the experience of integrating digital pathology for routine diagnosis in Paris Saclay Hospital’s pathology department, highlighting the transition to digital pathology, current progress, benefits to pathologist workflow, and future projects in the department.

How Co-Occurring Oncogenic Mutations Impact Clinical Outcomes

White Paper

This white paper from Qiagen discusses use cases for employing QCI Interpret for Oncology clinical decision support software to annotate and interpret co-mutations, genomic changes in associated pathways that may elicit complementary effects and may provide prognostic and predictive value.

Tracking the Progress of ERBB2-Targeted Therapies from Early Case Studies to Market with COSMIC Actionability

White Paper

This white paper from Qiagen describes tracking ERBB2-targeted therapies using COSMIC Actionability, a feature within the Catalogue of Somatic Mutations in Cancer that indicates the availability of drugs that target mutations in cancer and tracks the progress of clinical studies towards making new drugs available.

Know Your Biomarkers: How PRKD1 is Linked to Head and Neck Squamous Cell Carcinoma (HNSCC)

White Paper

This white paper from Qiagen describes the PRKD1 gene and its role in head and neck cancers, as well as how COSMIC, the Catalogue of Somatic Mutations in Cancer, can be used to explore mutations in PRKD1 and other genes related to head and neck cancer.

A Vital Victory in Serbia’s Fight Against Cancer

White Paper

This case study from Qiagen describes how clinical laboratory geneticists at the Institute for Oncology and Radiology of Serbia use the Human Somatic Mutation Database, or HSMD, which contains curated genomic content relevant to solid tumors and hematological malignancies.

Genetic Insights for Biopharmaceuticals: Propelling Drug Candidates into Therapeutic Assets

White Paper

This white paper from Thermo Fisher Scientific presents data describing how genetic analysis is enabling more rapid and efficient clinical trials, how the integration of genetic analysis technologies is evolving in the pharma and biotech spaces, and how Thermo Fisher Scientific genetic analysis solutions may enable a competitive advantage.

Streamline Your Adoptive Cell Therapy Program with Digital PCR

White Paper

This white paper from CellCarta describes the principals of digital PCR (dPCR) and how dPCR-based pharmacokinetics assays can de-risk adoptive cell therapy development.

The Role of Chimerism Following Hematopoietic Stem Cell Transplantation

White Paper

This white paper from Devyser details the role of chimerism in patients following hematopoietic stem cell transplantation, the utility of chimerism analysis as a tool for clinical decision making, and considerations for maximizing the potential of chimerism assays in the clinic.

How Co-Occurring Oncogenic Mutations Impact Clinical Outcomes

White Paper

Next-generation sequencing (NGS) has revealed comprehensive genomic tumor profiles and showed that the presence of a single somatic mutation can be insufficient to implicate a gene in the development of cancer. While initial studies of somatic mutations focused on the impact of single mutations, researchers are now investigating the cooperative effects induced by multiple mutations arising simultaneously in one tumor. The event of multiple mutations emerging concurrently is referred to as co-mutation or mutation co-occurrence. Co-mutations have been investigated in many tumor types, and studies have suggested that co-mutations might be a core determinant of oncogene-driven cancers.

This white paper from Qiagen presents use cases in acute myeloid leukemia and glioma demonstrating the importance of adequately annotating and interpreting co-mutations in human cancers, and how the presence of co-occurring mutations can inform diagnosis, prognosis, and therapy options.